Web Site Linking Policy

Spectrum Pharmaceuticals, Inc. (“Spectrum”) ordinarily does not prohibit links to this Web Site, provided that any such link does not improperly connote an endorsement by or affiliation with Spectrum, or otherwise adversely impact Spectrum, and pursuant to the terms below.

If you are interested in linking to this Web Site or any other Spectrum-owned web sites, please notify Spectrum Pharmaceuticals by sending an e-mail to info@sppirx.com. Include your name, your organization name, contact information (such as a phone number and/or e-mail address), as well as the URL of your site and a list of any URLs from which you intend to link to this site.

By linking to any page on the Spectrum Web Sites, you hereby agree to be bound by the terms and conditions as set forth below.

Links may be text-based using the words: “advance-study.com,” “Spectrum,” “Spectrum Pharmaceuticals, Inc.,” or “Spectrum.com” (the “Spectrum Marks”). You may not use any Spectrum logo as a link. By linking, you acknowledge and agree that, other than as set forth herein, all rights to the Spectrum Marks, other Spectrum marks, the content appearing on the Spectrum Web Site and the design of the Spectrum Web Site belong to Spectrum Pharmaceuticals, Inc. Nothing contained herein shall be construed as conferring by implication, estoppel, or otherwise any license or right under any patent, trademark, or copyright owned by Spectrum Pharmaceuticals, Inc.

You may not create frames around any of the pages of the Spectrum Web Sites or use other techniques that alter in any way the visual presentation or appearance of any of the Spectrum Web Sites.

You must not misrepresent your relationship with any Spectrum product or Spectrum Pharmaceuticals, Inc. (or any Spectrum-owned business entity, Spectrum subsidiary, or Spectrum-affiliated business entity) or present false or misleading impressions about any Spectrum product or Spectrum Pharmaceuticals, Inc. (or any Spectrum-owned business entity, Spectrum subsidiary, or Spectrum-affiliated business entity). No links to any Spectrum Web Site may be used in a manner that implies or suggests that Spectrum approves or endorses you, your Web site, or your goods and services (in all cases, except as Spectrum may have agreed separately with you in a signed writing).

Spectrum has no responsibility or liability for any content appearing on your Web site. You agree to indemnify and defend Spectrum against all claims arising out of or based upon your Web site.

No link(s) may appear on any page on your Web site or within any context containing content or materials that may be interpreted as libelous; obscene or criminal; or which infringes, otherwise violates, or advocates the infringement or other violation of, any third-party rights.

Spectrum may at any time, in its sole discretion, without cause, terminate your right to link to any Web pages of any Spectrum Web Site. In such event, upon request, you agree to immediately remove all links to any Spectrum Web Site and to cease using the Spectrum Marks. Spectrum reserves the right to change this linking policy at any time without notice, and such changes will be deemed effective upon posting. Changes will be posted on this page.

This Web Site Linking Policy is effective as of June 23, 2016.

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.

RECOVER is a clinical study for people who are about to start their first treatment for breast cancer. The purpose of this study is to compare eflapegrastim and pegfilgrastim (also known as Neulasta®*) while you receive TC chemotherapy for early-stage breast cancer, by collecting blood samples and will be looking at the number of white blood cells, including neutrophils, being produced by the body.

*Disclaimer Third Parties

All product and company names are trademarks (TM) or registered trademarks (®) of their respective holders. Use of them does not imply any affiliation, approval, license or endorsement by them.

Neulasta® is a registered trademark of Amgen Inc.

Terms of Use

Privacy Policy

Web Site Linking Policy

Eflapegrastim (also known as SPI-2012) is a medication currently being tested and has yet to receive approval from the Food and Drug Administration (FDA).

© 2017 Spectrum Pharmaceuticals, Inc. All Rights Reserved.